Prevention of Diabetes by inhibition of Tyrosine Phosphatases

Mokdad AH , Ford ES , Bowman BA , Dietz WH , Vinicor F , Bales VS , Marks JS . Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 289: 76–79, 2003.

Narayan KMV , Boyle JP , Thompson TJ , Sorensen SW , Williamson DF . Lifetime risk for diabetes mellitus in the United States. JAMA 290: 1884–1890, 2003.

Cruz ML , Shaibi GQ , Weigensberg MJ , Spruijt-Metz D , Ball GDC , Goran Ml . Pediatric obesity and insulin resistance: chronic disease risk and implications for treatment and prevention beyond body weight modification. Annu Rev Nutr 25: 435–468, 2005.

Sinha R , Fisch G , Teague B , Tamborlane WV , Banyas B , Allen K , Savoye M , Rieger V , Taksali S , Barbetta G , Sherwin RS , Caprio S . Prevalence of impaired glucose tolerance among children and adolescents with marked obesity. N Engl J Med 346: 802–810, 2002.

Sheehan MT . Current therapeutic options in type 2 diabetes mellitus: a practical approach. Clin Med Res 1: 189–200, 2003.

Winter CL , Lange JS , Davis MG , Gerwe GS , Downs TR , Peters KG , Kasibhatla B . A nonspecific phosphotyrosine phosphatase inhibitor, bis(maltolato)oxovanadium(IV), improves glucose tolerance and prevents diabetes in Zucker diabetic fatty rats. Exp Biol Med (Maywood) 230: 207–216, 2005.

Saltiel AR , Pessin JE . Insulin signaling pathways in time and space. Trends Cell Biol 12: 65–71, 2002.